WHO preferred product characteristics of monoclonal antibodies for passive immunization against respiratory syncytial virus (‎RSV)‎ disease

Overview

This document describes World Health Organization (WHO) preferences for characteristics of monoclonal antibody (mAb) products used for passive immunization against severe respiratory syncytial virus (RSV) disease in infants. These preferences are shaped by the global unmet public health need in priority disease areas for which WHO encourages the development of vaccines and other preventive interventions suitable for use in low- and middle-income countries (LMICs).

While many characteristics are the same as those preferred in highincome countries, there are some characteristics that might be unique to LMIC settings.